Answers are grounded in this paper and cite their sources.
Clinical review uncovers widespread antipsychotic polypharmacy in psychotic illnesses, highlighting opportunities to enhance monotherapy alongside risks of unmonitored prescribing.
Antipsychotic polypharmacy is a surprisingly frequent occurrence that can be both justified and unjustifed, depending on how it is used. To the extent that this phenomenon has been unrecognized and is not being studied, it is a "dirty little secret." To the extent that careful clinicians have uncovered a useful strategy for boosting the effectiveness of available antipsychotic monotherapies, it represents an opportunity to improve the outcomes of patients with psychotic illnesses.
No takes yet. Share an insight, caveat, or question.
Stephen M. Stahl (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: